



ASX ANNOUNCEMENT

14 July 2014

Cynata Contracts Leading CRO to Conduct Preclinical Studies with Cymerus™ Stem Cell Product

Cynata Therapeutics Ltd (ASX:CYP) announced today that it has signed an agreement with WuXi AppTec (NYSE:WX), a leading global biopharmaceutical contract research organisation, to conduct preclinical safety studies with Cynata's unique Cymerus™ stem cell technology. The studies will be conducted at WuXi AppTec's GLP-compliant, FDA-registered facility in St Paul, Minnesota.

Cynata's preclinical program has been designed following an in-depth review of the current regulatory expectations in major jurisdictions worldwide, which has included direct interaction with regulatory authorities. The data generated from these studies will be a key pillar supporting Cynata's planned clinical trial program, which is expected to commence next year.

"We are very pleased to have engaged an organisation as proficient and well regarded as WuXi AppTec to conduct these vital studies", said Dr Kilian Kelly, Cynata's Vice President, Product Development. "The team of scientists that will run this project has extensive experience conducting similar studies with other cellular therapy products, which gives us confidence that our program will be conducted to the highest standards. We expect these safety studies, as part of the broader preclinical program, to facilitate regulatory clearance of our planned clinical trial in graft versus host disease".

The Cymerus™ technology facilitates large scale production of MSCs from a single donor, a key element for pharmaceutical companies as they move into stem cell medicine.

Media contacts:

Dr Ross Macdonald, CEO: Tel: 0412 119 343; email ross.macdonald@cynata.com

Dr Stewart Washer, Executive Chairman: Tel: 0418 288 212; email stewart.washer@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.